Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.51 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.51 |
| ▸ | PREP | P48147 | 4/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | SPR | P35270 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17592860 | 1.00 | CHRM2 (0.51) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL17592862 | 1.00 | CHRM2 (0.51) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL19728175 | 1.00 | CHRM2 (0.51) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL30068303 | 0.94 | CHRM2 (0.58) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL4312871 | 0.94 | CHRM2 (0.58) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL31341776 | 0.87 | CHRM2 (0.54) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL31390583 | 0.87 | CHRM2 (0.54) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL30967988 | 0.85 | CHRM2 (0.53) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL30967979 | 0.85 | CHRM2 (0.53) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL16237474 | 0.83 | CHRM2 (0.46) | CHRM2CHRM1CHRM3PREPHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10577363-B2 | Substituted piperidine compounds | Epizyme, Inc. (US) | 2020-03-03 | — | — | US | disclosed |
| US-20170362217-A1 | Substituted Piperidine Compounds | Epizyme, Inc. (US) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10577363-B2 | Substituted piperidine compounds | SMYD3, SMYD2, SNRPD3 | CHRM2 3204/4885CHRM1 3552/4885CHRM3 3863/4885 |
| US-20170362217-A1 | Substituted Piperidine Compounds | SMYD3, SMYD2, SNRPD3 | CHRM2 3204/4885CHRM1 3552/4885CHRM3 3863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.